TG Therapeutics Stock Plunges 17.99% on Missed Earnings Despite Strong Revenue Surging Trading Volume Ranks 325th in Market Activity

On August 4, 2025, TG Therapeutics (TGTX) fell 17.99% as its Q2 earnings missed estimates, despite revenue outperforming forecasts. The stock saw a 314.12% surge in trading volume, ranking 325th in market activity. Earnings per share (EPS) came in at $0.17, below the $0.32 consensus, while revenue rose to $141.1 million, a 91% year-over-year increase driven by strong performance in BREONVY. Management raised full-year revenue guidance to $575 million and highlighted progress on subcutaneous BRIONVI development, with potential launch in 2028.

The earnings call emphasized robust commercial execution, including a 16% sequential revenue growth and expanded market share in IV anti-CD20 therapies. Operating expenses increased to $71 million, reflecting R&D investments in subcutaneous formulations and clinical trials. Despite the EPS shortfall, gross profit margins remained strong at 87.4%. Analysts noted mixed sentiment, with Zacks assigning a #3 (Hold) rating, while the company’s 52-week high of $46.48 contrasted with its current price near $32.40.

Management highlighted strategic initiatives, including a Phase III trial for subcutaneous BRIONVI and a simplified dosing regimen for IV BREONVY. CEO Michael Weiss underscored the product’s potential to become a multibillion-dollar brand in relapsing MS. However, challenges remain, including high operating costs and competition in the CD20 class. The company’s cash reserves of $279 million provide flexibility for pipeline expansion but face pressure from rising expenses.

The backtest of a strategy buying top 500 liquid stocks and holding for one day returned 166.71% from 2022 to present, far outperforming the benchmark’s 29.18%. This underscores liquidity’s role in short-term performance, particularly in volatile markets, where capturing liquidity-driven momentum can yield significant outperformance relative to traditional approaches.